46A44EBC-2B07-45EF-93EF-3F537A8AF49B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.764783180026281
- age_years
- 64
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.604
- MYC_TARGETS_V1+0.602
- E2F_TARGETS+0.575
- MYC_TARGETS_V2+0.566
- OXIDATIVE_PHOSPHORYLATION+0.540
- DNA_REPAIR+0.509
- G2M_CHECKPOINT+0.493
- INTERFERON_GAMMA_RESPONSE+0.482
- MTORC1_SIGNALING+0.422
- UNFOLDED_PROTEIN_RESPONSE+0.373
Top 10 suppressed
- KRAS_SIGNALING_DN-0.422
- HEDGEHOG_SIGNALING-0.387
- MYOGENESIS-0.284
- ESTROGEN_RESPONSE_EARLY-0.241
- SPERMATOGENESIS-0.231
- ESTROGEN_RESPONSE_LATE-0.126
- APICAL_SURFACE-0.098
- APICAL_JUNCTION-0.069
- UV_RESPONSE_DN-0.061
- HYPOXIA-0.044
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2E040577-EA0C-4876-9F43-A180DA38F733 | — | — | 0.948 |
| 2 | 812834CD-DA8F-4C0C-A49E-31D4A882D0E0 | — | — | 0.944 |
| 3 | C14BEAAE-A766-4ADE-A9B4-674D8717591F | — | — | 0.938 |
| 4 | 05C1C0CC-8EAE-4924-B041-D448D280C192 | — | — | 0.938 |
| 5 | D9385661-DBBA-4AF7-B7E6-857BF84CF7CD | — | — | 0.930 |
| 6 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.927 |
| 7 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.919 |
| 8 | C8E7072F-6FBB-4BF8-8917-0C0CBDAF7605 | — | — | 0.918 |
| 9 | 1A0F3795-92C5-4887-8CD0-B19C763CF6EF | — | — | 0.917 |
| 10 | 3941F338-3165-4CCA-9108-65A110186E6B | — | — | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.604 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.602 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.575 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.566 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.509 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.493 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.482 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.422 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.373 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.315 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.299 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.295 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.292 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.278 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.243 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.225 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.213 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.205 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.181 | Inavolisib | — uncovered |